Translational Development Acquisition (TDAC) Income from Continuing Operations (2024 - 2026)
Translational Development Acquisition's (TDAC) quarterly Income from Continuing Operations came in at 281161.0 in Q1 2026, up 19.07% YoY from 236132.96 in Q1 2025, and down 73.19% on a QoQ basis from 162345.0 in Q4 2025.
Translational Development Acquisition (TDAC) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Translational Development Acquisition (TDAC) has 3 years of Income from Continuing Operations data on file, last reported at 281161.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 19.07% year-over-year to 281161.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 878291.0 (changed N/A YoY) and the FY2025 annual result came in at 944538.0, down 381.03% from the prior year.
- Income from Continuing Operations declined to 281161.0 in Q1 2026, from 162345.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 61283.0 in Q3 2024 to a low of 347408.0 in Q1 2025.
- A 3-year average of 202910.29 and a median of 213658.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 248.64% — and 2026, when it grew 19.07%.
- Tracing TDAC's Income from Continuing Operations over 3 years: stood at 133390.0 in 2024, then retreated by 21.71% to 162345.0 in 2025, then sank by 73.19% to 281161.0 in 2026.
- The last three Income from Continuing Operations figures came in at 281161.0 (Q1 2026), 162345.0 (Q4 2025), and 213658.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oxley Bridge Acquisition | 585.76 Mn | 585.76 Mn | - | 2.11 Mn |
| 2 | Launch Two Acquisition | 557.86 Mn | 557.86 Mn | - | 1.95 Mn |
| 3 | Drugs Made In America Acquisition | 507.00 Mn | 507.00 Mn | - | 4.40 Mn |
| 4 | Cantor Equity Partners IV | 468.00 Mn | 468.00 Mn | - | 3.92 Mn |
| 5 | GP-Act III Acquisition | 401.06 Mn | 401.06 Mn | - | 290,121.00 |
| 6 | Aldel Financial | 397.49 Mn | 397.49 Mn | - | 2.11 Mn |
| 7 | Republic Digital Acquisition | 389.25 Mn | 388.51 Mn | - | 2.65 Mn |
| 8 | Gores Holdings X | 385.06 Mn | 384.87 Mn | - | 1.88 Mn |
| 9 | Agriculture & Natural Solutions Acquisition | 377.29 Mn | 377.04 Mn | - | - |
| 10 | Translational Development Acquisition | 182.66 Mn | 182.57 Mn | - | -661,050.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -281,161.00 |
| Dec 31, 2025 | -162,345.00 |
| Sep 30, 2025 | -213,658.00 |
| Jun 30, 2025 | -221,127.00 |
| Mar 31, 2025 | -347,408.00 |
| Dec 31, 2024 | -133,390.00 |
| Sep 30, 2024 | -61,283.00 |